Vivos Therapeutics (VVOS) EBT Margin (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly EBT Margin of 150.77% for Q1 2026, down 2265.0% year-over-year from 6.96% in Q1 2025, and up 17.09% quarter-over-quarter from 181.85% in Q4 2025.
Vivos Therapeutics (VVOS) EBT Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported EBT Margin for 7 consecutive years, with 150.77% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 2265.0% year-over-year to 150.77%; the TTM figure through Mar 2026 stood at 128.36% (down 5115.0% YoY), while the FY2025 annual figure was 121.71%, down 4724.0% from the prior year.
- EBT Margin climbed to 150.77% in Q1 2026 per VVOS's latest filing, from 181.85% in the prior quarter.
- Across five years, EBT Margin topped out at 288.39% in Q4 2023 and bottomed at 181.85% in Q4 2025.
- Historically, EBT Margin has averaged 91.48% across 5 years, with a median of 127.98% in 2022.
- Annual changes were most pronounced in 2023 — EBT Margin surged 44508 bps — and 2024, when it plunged 36641 bps.
- Vivos Therapeutics' EBT Margin stood at 156.68% in 2022, then jumped by 284 bps to 288.39% in 2023, then sank by 127 bps to 78.02% in 2024, then plunged by 133 bps to 181.85% in 2025, then climbed by 17 bps to 150.77% in 2026.
- Business Quant data shows VVOS's EBT Margin at 150.77% in Q1 2026, 181.85% in Q4 2025, and 79.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.61 Bn | 194.01 Bn | 7.27 Bn | 12.10% |
| 2 | Stryker | 127.81 Bn | 124.34 Bn | 4.50 Bn | 23.74% |
| 3 | Medtronic | 119.04 Bn | 109.82 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 73.68 Bn | 73.14 Bn | 3.85 Bn | 19.48% |
| 5 | Edwards Lifesciences | 51.96 Bn | 47.71 Bn | 1.35 Bn | 29.86% |
| 6 | Dexcom | 34.36 Bn | 32.41 Bn | 830.00 Mn | 24.27% |
| 7 | GE HealthCare Technologies | 33.83 Bn | 31.72 Bn | 2.18 Bn | 13.09% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 8.91% |
| 9 | Steris | 23.06 Bn | 22.58 Bn | 684.20 Mn | 18.32% |
| 10 | Vivos Therapeutics | 4.97 Mn | 3.17 Mn | 2.95 Mn | -107.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -150.77% |
| Dec 31, 2025 | -181.85% |
| Sep 30, 2025 | -79.61% |
| Jun 30, 2025 | -131.23% |
| Mar 31, 2025 | -128.12% |
| Dec 31, 2024 | -78.02% |
| Sep 30, 2024 | -67.77% |
| Jun 30, 2024 | -47.61% |
| Mar 31, 2024 | -110.06% |
| Dec 31, 2023 | 288.39% |
| Sep 30, 2023 | -63.41% |
| Jun 30, 2023 | -162.83% |
| Mar 31, 2023 | -44.15% |
| Dec 31, 2022 | -156.68% |
| Sep 30, 2022 | -127.98% |
| Jun 30, 2022 | -167.11% |
| Mar 31, 2022 | -146.30% |
| Dec 31, 2021 | -168.68% |
| Sep 30, 2021 | -119.95% |
| Jun 30, 2021 | -89.90% |